Disulfide disruption reverses mucus dysfunction in allergic airway disease

Leslie E. Morgan, Ana M. Jaramillo, Siddharth K. Shenoy, Dorota Raclawska, Nkechinyere A. Emezienna, Vanessa L. Richardson, Naoko Hara, Anna Q. Harder, James C. NeeDell, Corinne E. Hennessy, Hassan M. El-Batal, Chelsea M. Magin, Diane E. Grove Villalon, Gregg Duncan, Justin S. Hanes, Jung Soo Suk, David J. Thornton, Fernando Holguin, William J. Janssen, William R. ThelinChristopher M. Evans

Research output: Contribution to journalArticlepeer-review


Airway mucus is essential for lung defense, but excessive mucus in asthma obstructs airflow, leading to severe and potentially fatal outcomes. Current asthma treatments have minimal effects on mucus, and the lack of therapeutic options stems from a poor understanding of mucus function and dysfunction at a molecular level and in vivo. Biophysical properties of mucus are controlled by mucin glycoproteins that polymerize covalently via disulfide bonds. Once secreted, mucin glycopolymers can aggregate, form plugs, and block airflow. Here we show that reducing mucin disulfide bonds disrupts mucus in human asthmatics and reverses pathological effects of mucus hypersecretion in a mouse allergic asthma model. In mice, inhaled mucolytic treatment loosens mucus mesh, enhances mucociliary clearance, and abolishes airway hyperreactivity (AHR) to the bronchoprovocative agent methacholine. AHR reversal is directly related to reduced mucus plugging. These findings establish grounds for developing treatments to inhibit effects of mucus hypersecretion in asthma.

Original languageEnglish (US)
Article number249
JournalNature communications
Issue number1
StatePublished - Dec 1 2021

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)


Dive into the research topics of 'Disulfide disruption reverses mucus dysfunction in allergic airway disease'. Together they form a unique fingerprint.

Cite this